Hims & Hers Health, Inc. HIMS
We take great care to ensure that the data presented and summarized in this overview for Hims & Hers Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HIMS
View all-
Vanguard Group Inc Valley Forge, PA18.7MShares$896 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA18.6MShares$890 Million0.14% of portfolio
-
Black Rock Inc. New York, NY14.6MShares$699 Million0.01% of portfolio
-
New View Hms Spv Partners, LLC Burlingame, CA9.66MShares$463 Million100.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA8.21MShares$394 Million1.84% of portfolio
-
Goldman Sachs Group Inc New York, NY8.16MShares$391 Million0.06% of portfolio
-
State Street Corp Boston, MA7.04MShares$338 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.87MShares$329 Million0.49% of portfolio
-
Morgan Stanley New York, NY5.53MShares$265 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$228 Million0.02% of portfolio
Latest Institutional Activity in HIMS
Top Purchases
Top Sells
About HIMS
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Insider Transactions at HIMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2025
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,581
-9.02%
|
$555,888
$48.05 P/Share
|
|
Aug 13
2025
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,581
+14.99%
|
$57,905
$5.01 P/Share
|
|
Aug 11
2025
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,572
-1.65%
|
$131,172
$51.64 P/Share
|
|
Aug 07
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
660,000
-22.96%
|
$33,000,000
$50.58 P/Share
|
|
Aug 06
2025
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
60,000
-26.09%
|
$3,180,000
$53.58 P/Share
|
|
Aug 01
2025
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
250
-0.09%
|
$16,000
$64.44 P/Share
|
|
Aug 01
2025
|
Michael Chi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+0.09%
|
$2,750
$11.53 P/Share
|
|
Jul 31
2025
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
26,350
-8.64%
|
$1,765,450
$67.0 P/Share
|
|
Jul 31
2025
|
Michael Chi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,350
+2.15%
|
$237,150
$9.32 P/Share
|
|
Jul 28
2025
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,572
-1.63%
|
$149,176
$58.7 P/Share
|
|
Jul 24
2025
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,100
-0.75%
|
$119,700
$57.52 P/Share
|
|
Jul 24
2025
|
Michael Chi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+0.74%
|
$10,500
$5.01 P/Share
|
|
Jul 23
2025
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,750
-4.7%
|
$770,000
$56.0 P/Share
|
|
Jul 23
2025
|
Michael Chi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,750
+1.51%
|
$96,250
$7.79 P/Share
|
|
Jul 21
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
125,335
-24.27%
|
$6,141,415
$49.5 P/Share
|
|
Jul 21
2025
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
125,335
+19.11%
|
$250,670
$2.43 P/Share
|
|
Jul 16
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
47,534
-10.06%
|
$2,376,700
$50.53 P/Share
|
|
Jul 16
2025
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,792
-2.94%
|
$139,600
$50.58 P/Share
|
|
Jul 14
2025
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,581
-17.64%
|
$544,307
$47.7 P/Share
|
|
Jul 14
2025
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,587
+10.36%
|
$37,935
$5.01 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 5.59M shares |
|---|---|
| Open market or private purchase | 5K shares |
| Payment of exercise price or tax liability | 1.1M shares |
|---|---|
| Open market or private sale | 5.63M shares |
| Bona fide gift | 10K shares |